“The next hepatitis C.”
That’s what another liver disease, non-alcoholic steatohepatitis (NASH), has been called. The global market for NASH drugs could be $40 billion annually -- and there are no approved treatments for the disease. Gilead Sciences (NASDAQ:GILD) is sorely in need of something beyond hepatitis C, with sliding sales of its hep-C drugs Harvoni and Sovaldi.
Gilead has high expectations for its late-stage NASH candidate GS-4997.
